VistaGen Therapeutics Announces Last Patient Completes Dosing in the ELEVATE Phase 2 Clinical Study of AV-101 for Major Depressive Disorder
Stock Information for Vistagen Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.